Catalyst Wire Dossier Catalyst Wire Dossier

Autologous CD8+ antigen-specific T cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous CD8+ antigen-specific T cells, covering 2026-02-17 to 2026-02-17. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma [Phase 1]

See pricing